Premium
Osteoblast growth and bone‐healing response to three‐dimensional poly(ε‐caprolactone fumarate) scaffolds
Author(s) -
Kim Jinku,
Sharma Aditi,
Runge Brett,
Waters Heather,
Doll Bruce,
McBride Sean,
Alvarez Pedro,
Dadsetan Mahrokh,
Yaszemski Michael J.,
Hollinger Jeffrey O.
Publication year - 2012
Publication title -
journal of tissue engineering and regenerative medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.835
H-Index - 72
eISSN - 1932-7005
pISSN - 1932-6254
DOI - 10.1002/term.442
Subject(s) - caprolactone , osteoblast , chemistry , bone healing , biomedical engineering , biochemistry , anatomy , medicine , organic chemistry , in vitro , polymer , copolymer
Poly(ε‐caprolactone fumarate) (PCLF) scaffold formulations were assessed as a delivery system for recombinant human bone morphogenetic protein (rhBMP‐2) for bone tissue engineering. The formulations included PCLF with combinations of poly(vinyl alcohol) (PVA) and hydroxyapatite (HA). The assessments included in vitro and in vivo assays. In vitro assays validated cell attachment using a pre‐osteoblast cell line (MC3T3‐E1). Additionally, in vitro release profiles of rhBMP‐2 from PCLF scaffolds were determined up to 21 days. The data suggested that PCLF incorporated with PVA and HA accelerated rhBMP‐2 release and that the released protein was bioactive. For the in vivo study, a critical‐sized defect (CSD) model in rabbit calvaria was used to test PCLF scaffolds. At 6 weeks post‐implantation, significantly more bone formation was measured in PCLF scaffolds containing rhBMP‐2 than in scaffolds without rhBMP‐2. In conclusion, we demonstrated that PCLF delivered biologically active rhBMP‐2, promoted bone healing in a CSD and has potential as a bone tissue engineering scaffold. Copyright © 2011 John Wiley & Sons, Ltd.